notice received, page-9

Hi all. Interesting and I suspect unexpected TH.

for my tuppence worth the fraise " significant transaction" is the key.

This rules out the expected IP valuation.

Also if you check transgenes overnight trading the range is in the €11 area down on previous highs but expected due to the CR at €10.00 previously anounced. Also the outside date for any news re novartis is mid April so its fare to rule out the any progress on this front.

My pick. Co-ex-Gene is a powerful platform technology from which TG4010, TG4001 and for that matter TG4040 (which VHL no longer has an interest) have there origins. There is so many more potential applications (HIV being one) and I suspect interest in these other non taken areas.

So im guessing and guessing only that another license involving another party is in the wind.